Идёт набор NCT06904820

Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®

— Наблюдательное Viral Hepatitis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально: Состояния в реестре: Viral Hepatitis. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Франция
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

The "Scanvir" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a "test, treat and cure" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.

Подробное описание

According to the French recommendations, eliminating hepatitis C virus by 2025 could be a realistic public health goal in this country. A total of 71,466 patients had treatment initiation between 2015 and 2019. It is estimated that 100 000 people are still infected in 2019.

To meet these ambitious objectives, effective screening policies should be intensified and access to treatment promoted through new care strategies for patients who escape the usual care pathways i.e. people who inject drugs (PWIDs), prisoners, migrants and vulnerable populations.

PWIDs represent a large proportion of patients to be screened and treated. It's still not possible to accurately evaluate the number of drug users who are infected with HCV (45 000 people estimated).

Drug users sharing needles and syringes have poor access to treatment. Dealing with PWIDs in addiction care centers (CSAPA and CAARUD in France) is one way to promote HCV testing, and to keep them in the care pathway. This population requires dedicated models that reduce barriers to care: harm reductions policies, access to therapy in real time and follow-up for the detection of reinfection. So the investigator designed and applied a new innovative concept to test, treat and cure PWIDs in their own environment, called the SCANVIR program, initially tested in four French departments with a regional and now national extension.

Первичные конечные точки

Evaluate the acceptability and the feasibility of simultaneous screening for viral hepatitis B, C and HIV among drug users and vulnerable populations in non-conventional structures using a triple method with RTD and FibroScan® and GeneXpert®. [Срок оценки: from enrollment to the end of the subject participation at the end of the day]

Вторичные конечные точки (8)

Reinforce screening for hepatitis B (HBV), hepatitis Delta (HDV) and HIV, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Reinforce education to prevent the risk of viral transmission, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Encourage HBV vaccination, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Evaluate the feasibility of PCR (GeneXpert/Buvard), [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Reinforce education to prevent the risk of viral transmission, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Provide social support, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Offer rapid treatment to HCV-positive patients in precarious situations, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]
Assess associated co-morbidities: alcohol, cannabis, drug misuse, associated psychiatric pathologies, [Срок оценки: from enrollment to the end of the subject participation at the end of the day]

Критерии участия

Критерии включения

Adult 18 and over
Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
Patient not opposed to research